Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions

Pancreatic Cancer (PC) is a devastating malignancy with a poor prognosis and in-creasing morbidity. Current treatment strategies have limited efficacy in improving patient survival. Metabolic reprogramming is a hallmark of cancer and plays a key role in the pro-gression and maintenance of PC. PC cells exhibit a unique glutamine metabolism that is dis-tinct from other cancer types. The non-classical pathway of glutamine metabolic reprogram-ming plays a "permissive role" in the survival and proliferation of PC cells, mainly by affect-ing the redox homeostasis of the cells. In this review, we compare and contrast the canonical and non-canonical glutamine metabolic pathways and highlight recent advances in targeting non-canonical glutamine metabolism for therapeutic intervention. This may provide novel in-sights and opportunities for exploiting glutamine metabolic reprogramming in PC treatment.

Authors

Institutions

Publication Details

Journal
Current Cancer Drug Targets
Published
2025-01-22
DOI
https://doi.org/10.2174/0115680096357993241206072609
Citations
1
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions

Chengxia Kan, Yuqun Wang, Mingling Wang, Xiaodong Sun et al.
1 citations
Current Cancer Drug Targets
Cancer, Hypoxia, and Metabolism
0.94
article

Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions

Chengxia Kan, Yuqun Wang, Mingling Wang, Xiaodong Sun, Fangbing Ren, Kai‐Liang Zhang, Hongxi Sun, Wenqiang Zhang, Yanhui Ma, Fang Han
article en
1 citations

Abstract

Pancreatic Cancer (PC) is a devastating malignancy with a poor prognosis and in-creasing morbidity. Current treatment strategies have limited efficacy in improving patient survival. Metabolic reprogramming is a hallmark of cancer and plays a key role in the pro-gression and maintenance of PC. PC cells exhibit a unique glutamine metabolism that is dis-tinct from other cancer types. The non-classical pathway of glutamine metabolic reprogram-ming plays a "permissive role" in the survival and proliferation of PC cells, mainly by affect-ing the redox homeostasis of the cells. In this review, we compare and contrast the canonical and non-canonical glutamine metabolic pathways and highlight recent advances in targeting non-canonical glutamine metabolism for therapeutic intervention. This may provide novel in-sights and opportunities for exploiting glutamine metabolic reprogramming in PC treatment.

Current Cancer Drug TargetsVol. 25
Second Hospital of Shandong University (CN)
Good health and well-being
Openalex Percentile: Top 29%
Cancer, Hypoxia, and Metabolism
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions — Chengxia Kan, Yuqun Wang, et al. · Current Cancer Drug Targets (2025) | TGRS Research Map | TGRS